First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Codiak BioSciences, Inc. (CDNA): the developments shaping its investment case

    Follow the evidence affecting Codiak BioSciences, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Codiak BioSciences, Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-20 · 6 reports
    Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact
    Channel: Sector sentiment, potential for similar partnerships, competitive dynamics.
    watch· 1-3m

    Event impact log

    6 events mapped to CDNA since 2026-09-19. Evidence through 2026-09-20.

    DateEventChannelDirectionHorizonImpact
    2026-09-20Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pactSector sentiment, potential for similar partnerships, competitive dynamics.watch1-3m0.20
    2026-09-19Twist Bioscience partners with Eli Lilly on TuneLab AI discoveryIncreased competitive pressure in synthetic biology and antibody discovery services, potential for market share shifts.watch1-3m0.30
    2026-09-19Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discoveryIndirect sector sentiment and potential for future similar collaborations.watch1-3m0.20
    2026-09-19Twist Bioscience Partners with Eli Lilly on AI Drug Discovery PlatformIncreased competitive pressure in the AI-driven drug discovery and synthetic biology services market. Potential for other major pharma companies to seek similar partnerships.watch1-3m0.30
    2026-09-19Twist Bioscience Partners with Eli Lilly on AI-Powered TuneLab PlatformIncreased investor attention on companies leveraging AI/computational biology in life sciences, potential for similar partnerships.watch3-12m0.30
    2026-09-19Twist Bioscience Rallies 31% on Eli Lilly AI Drug Discovery CollaborationIncreased investor focus on AI-driven drug discovery platforms and related service providers, potential for sector re-rating.watch3-12m0.20

    Continue this research

    Build your Codiak BioSciences, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the CDNA entity page →

    Research Codiak BioSciences, Inc. · $399/mo